Jos Bloemers

Dr. Jos Bloemers


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
FMFlip Van Der Made
Flip Van Der Made
JBJos Bloemers
Jos Bloemers
WYWadi E. Yassem
Wadi E. Yassem
GKGunilla Kleiverda
Gunilla Kleiverda
WEWalter Everaerd
Walter Everaerd
ATAdriaan Tuiten
Adriaan Tuiten

1 March 2013 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
SPSaskia Poels
Saskia Poels
JBJos Bloemers
Jos Bloemers
KRKim van Rooij
Kim van Rooij
IGIrwin Goldstein
Irwin Goldstein
JGJeroen Gerritsen
Jeroen Gerritsen
ATAdriaan Tuiten
Adriaan Tuiten

1 March 2013 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
JBJos Bloemers
Jos Bloemers
KRKim van Rooij
Kim van Rooij
SPSaskia Poels
Saskia Poels
IGIrwin Goldstein
Irwin Goldstein
WEWalter Everaerd
Walter Everaerd
ATAdriaan Tuiten
Adriaan Tuiten

1 March 2013 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
KRKim van Rooij
Kim van Rooij
SPSaskia Poels
Saskia Poels
JBJos Bloemers
Jos Bloemers
IGIrwin Goldstein
Irwin Goldstein
JGJeroen Gerritsen
Jeroen Gerritsen
ATAdriaan Tuiten
Adriaan Tuiten

1 June 2009 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
JGJeroen Gerritsen
Jeroen Gerritsen
FMFlip Van Der Made
Flip Van Der Made
JBJos Bloemers
Jos Bloemers
DHDiana Van Ham
Diana Van Ham
GKGunilla Kleiverda
Gunilla Kleiverda
ATAdriaan Tuiten
Adriaan Tuiten

27 December 2017 in The Journal of Sexual Medicine
Verified
Journal Article
Open access
ATAdriaan Tuiten
Adriaan Tuiten
KRKim van Rooij
Kim van Rooij
JBJos Bloemers
Jos Bloemers
CEChristoph Eisenegger
Christoph Eisenegger
JHJack van Honk
Jack van Honk
JPJames G. Pfaus, PhD
James G. Pfaus, PhD
Background: In women, low sexual desire and/or sexual arousal can lead to sexual dissatisfaction and emotional distress, collectively defined as female sexual interest/arousal disorder (FSIAD). Few pharmaceutical treatment options are currently available.Aim: To investigate the efficacy and safety of 2 novel on-demand pharmacologic treatments that have been designed to treat 2 FSIAD subgroups (women with low sensitivity for sexual cues and women with dysfunctional over-activation of sexual inhibition) using a personalized medicine approach using an allocation formula based on genetic, hormonal, and psychological variables developed to predict drug efficacy in the subgroups.Methods: 497 women (21–70 years old) with FSIAD were randomized to 1 of 12 8-week treatment regimens in 3 double-blinded, randomized, placebo-controlled, dose-finding studies conducted at 16 research sites in the United States. Efficacy and safety of the following on-demand treatments was tested: placebo, testosterone (T; 0.5 mg), sildenafil (S; 50 mg), buspirone (B; 10 mg) and combination therapies (T 0.25 mg + S 25 mg, T 0.25 mg + S 50 mg, T 0.5 mg + S 25 mg, T 0.5 mg + S 50 mg, and T 0.25 mg + B 5 mg, T 0.25 mg + B 10 mg, T 0.5 mg + B 5 mg, T 0.5 mg + B 10 mg).Outcomes: The primary efficacy measure was the change in satisfying sexual events (SSEs) from the 4-week baseline to the 4-week average of the 8-week active treatment period after medication intake. For the primary end points, the combination treatments were compared with placebo and the respective monotherapies on this measure.Results: In women with low sensitivity for sexual cues, 0.5 mg T + 50 mg S increased the number of SSEs from baseline compared with placebo (difference in change [Δ] = 1.70, 95% CI = 0.57–2.84, P = .004) and monotherapies (S: Δ = 1.95, 95% CI = 0.44–3.45, P = .012; T: Δ = 1.69, 95% CI = 0.58–2.80, P = .003). In women with overactive inhibition, 0.5 mg T + 10 mg B increased the number of SSEs from baseline compared with placebo (Δ = 0.99, 95% CI = 0.17–1.82, P = .019) and monotherapies (B: Δ = 1.52, 95% CI = 0.57–2.46, P = .002; T: Δ = 0.98, 95% CI = 0.17–1.78, P = .018). Secondary end points followed this pattern of results. The most common drug-related side effects were flushing (T + S treatment, 3%; T + B treatment, 2%), headache (placebo treatment, 2%; T + S treatment, 9%), dizziness (T + B treatment, 3%), and nausea (T + S treatment, 3%; T + B treatment, 2%).Clinical Implications: T + S and T + B are promising treatments for women with FSIAD.Strengths and Limitations: The data were collected in 3 well-designed randomized clinical trials that tested multiple doses in a substantial number of women. The influence of T + S and T + B on distress and the potentially sustained improvements after medication cessation were not investigated.Conclusions: T + S and T + B are well tolerated and safe and significantly increase the number of SSEs in different FSIAD subgroups.